Ovide: Medgend

Search instead for covid

Ovide FDA Approved Drugs

DOCETAXEL [Docetaxel^{C₄₃H₅₃NO₁₄3H₂O}]

120mg/6ml (20mg/ml) (injection injectable)

140mg/7ml (20mg/ml) (injection injectable)

160mg/16ml (10mg/ml) (injection injectable)

160mg/8ml (20mg/ml) (injection injectable)

200mg/10ml (20mg/ml) (injection injectable)

20mg/0.5ml (40mg/ml) (injection injectable)

20mg/2ml (10mg/ml) (injection injectable)

20mg/ml (20mg/ml) (injection injectable)

80mg/2ml (40mg/ml) (injection injectable)

80mg/4ml (20mg/ml) (injection injectable)

80mg/8ml (10mg/ml) (injection injectable)

Hospira Inc^{Jun 23, 2016}
Actavis Llc^{Apr 12, 2013}
Sandoz^{Jun 29, 2011}
Accord Hlthcare^{Apr 20, 2012}
Eagle Pharms^{Dec 22, 2015}
Dfb Oncology Ltd^{Jan 20, 2017}
Dr Reddys Labs Ltd^{Nov 5, 2014}
Teva Pharms Usa^{Sep 16, 2015}
Jiangsu Hengrui Med^{Feb 15, 2017}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

IXEMPRA KIT [Ixabepilone^{C₂₇H₄₂N₂O₅S}]

15mg/vial (iv (infusion) injectable)

45mg/vial (iv (infusion) injectable)

R-pharm Us Llc^{Oct 16, 2007}

A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone.
Method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone.
Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.
Method of treating cancer, iv admin, lyophylized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

MALATHION [Malathion^{C₁₀H₁₉O₆PS₂}]

0.5% (topical lotion)

Suven Life^{May 23, 2012}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

OVIDE [Malathion^{C₁₀H₁₉O₆PS₂}]

0.5% (topical lotion)

Taro Pharm^{Aug 2, 1982}

Treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

TRIGLIDE [Fenofibrate^{C₂₀H₂₁ClO₄}]

160mg (oral tablet)

Skyepharma Ag^{May 7, 2005}

A method of treating dyslipidemia and dyslipoproteinemia using a dosage form that can provide an effective amount of fenofibrate to a patient in a fasted state which is at least 90% of the auc amount provided by the dosage form.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.